NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

2/3 UCLA

The only responsible parties are UCLA and Nature (plus their reviewers). NWBO is not involved, so skip choice 1, I find it kind of unlikely that the Nature side would be much of a holdup. So that leaves UCLA.

very reasonable that a review cycle could take some time, especially if authors are busy. This is an interim update on an ongoing P2, not exactly earth shaking news (despite what longs here think). I see no reason why all authors would drop what they are doing to respond to a review request code blue.

I also see no reason to sync with some external event. Sometimes papers are timed in conjunction with a conference presentation to avoid pre-disclosure. But with the pre-print already disclosed that looks unlikely (though I guess a possibility).

I previously thought it possible that UCLA would skip this if the final data was soon. But with the trial still ongoing, and looking like they might be still trying to reopen enrollment, the paper on the primary analysis could be years away.